专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016129890A1 A BIOMARKER FOR DIAGNOSING VASCULAR DISEASES AND THE USES THEREOF 审中-公开
标题翻译：用于诊断血管疾病的生物标志物及其用途
公开(公告)号：WO2016129890A1
公开(公告)日：2016-08-18
申请号：PCT/KR2016/001301
申请日：2016-02-05
申请人： EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION
发明人： KANG, Sang Won , KANG, Dong Hoon
IPC分类号： G01N33/68
CPC分类号： G01N33/6869 , C07K16/2866 , G01N33/5023 , G01N33/5061 , G01N33/6842 , G01N2333/5434 , G01N2500/10 , G01N2570/00 , G01N2800/32
摘要： Provided are a composition for diagnosing vascular disease including an agent measuring a level of interleukin 12 receptor β2 protein in the blood, and a kit for diagnosing vascular disease including the same. Further, provided is a method of providing information for diagnosing vascular disease, the method including the step of measuring a level of interleukin 12 receptor β2 protein in a blood sample separated from an individual suspected of having vascular disease. Furthermore, provided are a composition for preventing or treating vascular disease including an interleukin 12 receptor β2 activity inhibitor, and a method of screening a therapeutic agent for vascular disease, the method including the step of treating smooth muscle cells with a test agent for vascular disease treatment and measuring an expression level of interleukin 12 receptor β2. According to the present invention, when interleukin 12 receptor β2 is used as a biomarker for vascular disease, in particular, myocardial infarction or unstable angina, vascular disease, of which diagnosis has been performed only by angiography, can be diagnosed using blood in a rapid non-invasive economic manner. Accordingly, the early diagnosis of vascular disease is possible, since the disease has been diagnosed based on subjective symptoms after the appearance of ischemic symptoms with development of the disease. The promise of early diagnosis, prevention and treatment is realized.
摘要翻译：提供了用于诊断血管疾病的组合物，包括测量血液中白细胞介素12受体β2蛋白水平的试剂，以及用于诊断包括其的血管疾病的试剂盒。此外，提供了提供用于诊断血管疾病的信息的方法，所述方法包括测量从怀疑患有血管疾病的个体分离的血液样品中的白细胞介素12受体β2蛋白的水平的步骤。此外，提供了用于预防或治疗包括白细胞介素12受体β2活性抑制剂的血管疾病的组合物和筛选血管疾病治疗剂的方法，所述方法包括用血管病变试剂治疗平滑肌细胞的步骤治疗和测量白细胞介素12受体β2的表达水平。根据本发明，当白细胞介素12受体β2用作血管疾病的生物标志物时，特别是心肌梗塞或不稳定性心绞痛，血管病变（其诊断仅通过血管造影术进行）可以使用血液快速诊断无创经济方式。因此，血管疾病的早期诊断是可能的，因为该疾病已经基于发生该疾病的缺血性症状出现后的主观症状被诊断。实现早期诊断，预防和治疗的承诺。

2. 发明申请

WO2016088104A3 INDIRECT HOMOGENEOUS MOBILITY SHIFT ASSAYS FOR THE DETECTION OF BIOLOGICS IN PATIENT SAMPLES 审中-公开
标题翻译：用于检测患者样本中生物学的间接均质移动测定
公开(公告)号：WO2016088104A3
公开(公告)日：2016-08-18
申请号：PCT/IB2015059381
申请日：2015-12-04
申请人： NESTEC SA
发明人： SALBATO JARED , WESTIN STEFAN , CHI-KWAN LING NICHOLAS , JAIN ANJALI , SINGH SHARAT
IPC分类号： G01N33/537 , G01N33/58 , G01N33/94
CPC分类号： G01N33/94 , C07K14/5434 , C07K14/70546 , C07K2319/20 , C07K2319/50 , G01N33/537 , G01N33/564 , G01N33/58 , G01N33/6854 , G01N2333/54 , G01N2333/5434 , G01N2333/70546 , G01N2800/065 , G01N2800/52
摘要： The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble α4β7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.
摘要翻译：本发明提供使用尺寸排阻色谱法在患者样品中测量生物制剂如维多利珠单抗和乌斯卡单抗的敏感和特异性间接均匀迁移率变动测定。本发明的测定法特别有利于检测靶向复合物或大抗原（包括细胞表面蛋白，跨膜蛋白，重度糖基化蛋白质和多聚体蛋白质）的生物制剂的存在或水平，以及不能纯化的抗原，不纯的抗原，以及部分或基本纯化的抗原。本发明还提供了分离的可溶性α4β7整联蛋白异二聚体和分离的可溶性IL-12p40单体，其适用于本文所述的间接测定。

3. 发明申请

WO2015081067A3 METASTATIC MELANOMA BIOMARKERS 审中-公开
公开(公告)号：WO2015081067A3
公开(公告)日：2015-07-23
申请号：PCT/US2014067305
申请日：2014-11-25
申请人： BETH ISRALEL DEACONESS MEDICAL CT INC
发明人： SWANSON KENNETH D , WONG ERIC T
IPC分类号： G01N33/53 , G01N33/00
CPC分类号： G01N33/6869 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N33/5743 , G01N2333/521 , G01N2333/5406 , G01N2333/5409 , G01N2333/5412 , G01N2333/5421 , G01N2333/5428 , G01N2333/5434 , G01N2333/5437
摘要： The invention provides, inter alia, methods that are diagnostic and/or prognostic for cancer, particularly metastatic cancer, more particularly metastatic melanoma. These methods entail measuring the expression levels of immunokines— such as ILla, IL1 β, IL4, IL5, IL6, IL10, IL12, IL13, IL8, CCL3, CCL4, CCL5, CCL1 1, CCL17, CCL22, CXCL9, and CCXCL10— in a biological sample from a subject. Related kits, systems and methods of treatment are also provided.
摘要翻译：本发明尤其提供了用于癌症，特别是转移性癌症，特别是转移性黑素瘤的诊断和/或预后的方法。这些方法需要测量免疫球蛋白的表达水平，例如ILla，IL1β，IL4，IL5，IL6，IL10，IL12，IL13，IL8，CCL3，CCL4，CCL5，CCL1，CCL17，CCL22，CXCL9和CCXCL10- 来自受试者的生物样品。还提供了相关试剂盒，系统和治疗方法。

4. 发明申请

WO2011161438A3 BIOMARKERS FOR AUTISM SPECTRUM CONDITIONS, IN PARTICULAR ASPERGER SYNDROME 审中-公开
标题翻译：生物标志物对于特异性光谱条件，特别是ASPERGER综合征
公开(公告)号：WO2011161438A3
公开(公告)日：2013-01-03
申请号：PCT/GB2011051145
申请日：2011-06-20
申请人： CAMBRIDGE ENTPR LTD , BAHN SABINE , SCHWARZ EMANUEL
发明人： BAHN SABINE , SCHWARZ EMANUEL
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6896 , G01N2333/5434 , G01N2800/28 , G01N2800/30 , G01N2800/38 , G01N2800/56
摘要： The invention relates to a method of diagnosing or monitoring autism spectrum conditions, in particular Asperger syndrome.
摘要翻译：本发明涉及一种诊断或监测自闭症谱系状况，特别是阿斯伯格综合征的方法。

5. 发明申请

WO2013049362A8 METHOD OF TREATING MULTIPLE SCLEROSIS BY INTRATHECAL DEPLETION OF B CELLS AND BIOMARKERS TO SELECT PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS 审中-公开
标题翻译：通过B细胞和生物标志物的内分泌治疗多发性硬化的方法选择患有进行性多发性硬化症的患者
公开(公告)号：WO2013049362A8
公开(公告)日：2014-04-24
申请号：PCT/US2012057583
申请日：2012-09-27
申请人： US HEALTH
发明人： BIELEKOVA BIBIANA , HERMAN MATTHEW L
IPC分类号： C07K16/28 , A61P25/00 , A61P37/06 , G01N33/53
CPC分类号： C07K16/2887 , A61K9/0085 , A61K2039/505 , A61K2039/54 , A61K2039/545 , G01N33/6863 , G01N33/6869 , G01N33/6893 , G01N2333/521 , G01N2333/5434 , G01N2800/285 , G01N2800/52
摘要： Described herein are methods of treating multiple sclerosis (MS), such as secondary progressive MS (SPMS), by intrathecally administering a B cell depleting agent, such as rituximab, alone or in combination with intravenous administration of a B cell depleting agent. Also described is the use of IL-12p40, CXCL13, or both as CSF biomarkers for selecting a patient with progressive MS as a candidate for treatment with an intrathecal immunomodulatory therapy, and for identifying a progressive MS patient as having meningeal inflammation. The present disclosure also describes a method of evaluating the effectiveness of a therapy for treating progressive MS by measuring the level of IL-12p40, CXCL13, or both in the CSF of the patient before and after treatment. A decrease in the level of IL-12p40, CXCL13, or both after treatment indicates the therapy is effective for treating progressive MS.
摘要翻译：本文描述的是通过鞘内施用B细胞消耗剂（例如利妥昔单抗）单独或与静脉内施用B细胞消耗剂组合来治疗多发性硬化（MS），例如继发性进行性MS（SPMS）的方法。还描述了使用IL-12p40，CXCL13或两者作为CSF生物标志物，用于选择进行性MS的患者作为用鞘内免疫调节治疗治疗的候选者，以及用于鉴定进行性MS患者具有脑膜炎症。本公开还描述了通过测量治疗前后患者的CSF中的IL-12p40，CXCL13或两者的水平来评估治疗进行性MS的疗法的有效性的方法。治疗后IL-12p40，CXCL13或两者均降低，说明治疗对于进行性MS有效。

6. 发明申请

WO2013192191A1 DETERMINATION OF EFFICIENT TIME(S) FOR CHEMOTHERAPY DELIVERY 审中-公开
标题翻译：确定用于化疗方案的有效时间
公开(公告)号：WO2013192191A1
公开(公告)日：2013-12-27
申请号：PCT/US2013/046339
申请日：2013-06-18
申请人： MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
发明人： LEONTOVICH, Alexey A. , MARKOVIC, Svetomir N. , IVANOV, Leonid V.
IPC分类号： G06F19/00 , G01N33/49
CPC分类号： G01N33/57484 , A61K31/495 , G01N2333/4704 , G01N2333/475 , G01N2333/535 , G01N2333/54 , G01N2333/5428 , G01N2333/5434 , G01N2333/5437 , G01N2333/5443 , G01N2333/70514 , G01N2333/70553 , G01N2333/70596 , G01N2333/7155 , G01N2333/7158 , G06F19/00 , G06F19/12 , G06F19/3456 , G06F19/3481 , G16H50/50
摘要： A system and method for determination of efficient time(s) for chemotherapy delivery analyze time-dependent fluctuations of at least one biological variable measured in blood samples obtained from clinical patients and determine one or more favorable times for the pharmacological treatment of the patient. The systems and/or methods determine optimal time(s) for chemotherapy delivery based on serial measurements of the one or more biological variables. In some examples, the biological variables are immune variables. The determination may be patient-specific in the sense that only those biological variables satisfying desired threshold values may be used to determine optimal treatment times for each individual patient.
摘要翻译：用于确定化学药物递送的有效时间的系统和方法分析从临床患者获得的血液样品中测量的至少一种生物学变量的时间依赖性波动，并确定用于患者药理学治疗的一个或多个有利时间。系统和/或方法基于一个或多个生物变量的连续测量确定化学药物递送的最佳时间。在一些例子中，生物学变量是免疫变量。鉴于只有满足期望阈值的那些生物变量可用于确定每个单独患者的最佳治疗时间，该确定可以是患者特异性的。

7. 发明申请

WO2011161438A2 BIOMARKERS 审中-公开
标题翻译：生物标志物
公开(公告)号：WO2011161438A2
公开(公告)日：2011-12-29
申请号：PCT/GB2011/051145
申请日：2011-06-20
申请人： CAMBRIDGE ENTERPRISE LIMITED , BAHN, Sabine , SCHWARZ, Emanuel
发明人： BAHN, Sabine , SCHWARZ, Emanuel
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6896 , G01N2333/5434 , G01N2800/28 , G01N2800/30 , G01N2800/38 , G01N2800/56
摘要： The invention relates to a method of diagnosing or monitoring autism spectrum conditions, in particular Asperger syndrome.
摘要翻译：本发明涉及一种诊断或监测自闭症谱系状况，特别是阿斯伯格综合征的方法。

8. 发明申请

WO2009125219A2 MARKERS OF OOCYTE VIABILITY 审中-公开
标题翻译： OOCYTE VIABILITY标志
公开(公告)号：WO2009125219A2
公开(公告)日：2009-10-15
申请号：PCT/GB2009/050339
申请日：2009-04-07
申请人： UNIVERSITY OF LEEDS , THE LEEDS TEACHING HOSPITALS NHS TRUST , ORSI, Nicolas Michel , GOPICHANDRAN, Nadia , BARBER, Stuart , SHARMA, Vinay , WALKER, James Johnston
发明人： ORSI, Nicolas Michel , GOPICHANDRAN, Nadia , BARBER, Stuart , SHARMA, Vinay , WALKER, James Johnston
IPC分类号： G01N33/68
CPC分类号： G01N33/689 , G01N2333/52 , G01N2333/523 , G01N2333/535 , G01N2333/5406 , G01N2333/5412 , G01N2333/5425 , G01N2333/5434 , G01N2333/5443 , G01N2333/55 , G01N2333/56 , G01N2800/367
摘要： There is disclosed a method of determining the potential of individual oocyte to develop into a viable embryo, which method comprises establishing the concentration of any one or more of the markers identified in Table 2 in the follicular fluid of a single follicle from which said oocyte is derived and comparing the concentrations obtained to a reference concentration range that is established by comparing the concentration of said one or more markers from one or more follicles containing a fertilisation competent oocyte(s), wherein differential levels of said markers from said follicle to be tested compared to the reference range at least at the 5% significance level is predictive of a reduced potential of said oocyte to develop into a viable embryo following fertilisation.
摘要翻译：公开了一种确定个体卵母细胞发育成活的胚胎的潜力的方法，该方法包括确定表2中鉴定的任何一种或多种在所述卵母细胞为卵母细胞的单个滤泡的滤泡液中的浓度将获得的浓度与通过比较来自一个或多个含有受精卵感染卵母细胞的卵泡的所述一种或多种标记物的浓度而确定的参考浓度范围进行比较，其中所述标记物与所述待检测卵泡的差异水平与参考范围至少在5％显着性水平相比，预示着所述卵母细胞在受精后发育成活的胚胎的潜力降低。

9. 发明申请

WO2008070647A1 METHODS AND COMPOSITIONS FOR ASSESSING IL-12 OR THE NEUTRALIZATION OF IL-12 IN A SAMPLE 审中-公开
标题翻译：用于评估IL-12的方法和组合物或样品中IL-12的中和
公开(公告)号：WO2008070647A1
公开(公告)日：2008-06-12
申请号：PCT/US2007/086351
申请日：2007-12-04
申请人： WYETH , BRAUN, Ralph, Patrick , PALLADINO, Giuseppe
发明人： BRAUN, Ralph, Patrick , PALLADINO, Giuseppe
IPC分类号： G01N33/68
CPC分类号： G01N33/6866 , G01N33/6869 , G01N2333/5434 , G01N2333/57
摘要： Methods for detecting the presence or amount of Interleukin-12 (IL- 12), particularly human IL- 12, or antibodies that neutralize the activity of human IL- 12 in a human biological sample, involve incubating the biological sample with an NK cell line or progeny thereof. A correlation is determined between the presence or amount of IL- 12 (or anti-IL-12 antibodies) in the sample and the amount of gamma interferon (or a precursor activation factor or cytokine) secreted by the NK cells. For measuring antibodies, the sample is pre-incubated with IL-12. Levels of a cytokine or activation factor, such as IFN-γ, secreted by the NK cells when in the presence of IL-12 are then compared with a control level of the cytokine or activation factor secreted by the NK cells or progeny thereof in the presence of a known amount of IL-12 and without the biological sample. The presence of IL-12 or neutralizing anti-IL12 antibodies in the sample is indicated by a variation, e.g., an elevation or reduction, in the level of the secreted cytokine or activation factor in the sample as compared to the control level. These methods are useful for monitoring or determining the presence of IL-12 in a sample or neutralizing antibodies generated to IL-12 when the IL-12 is delivered as a vaccine adjuvant and in clinical situations wherein IL-12 enhancement or diminution is involved, among others.
摘要翻译：用于检测白细胞介素-12（IL-12）特别是人IL-12的存在或量的方法或中和人体生物样品中人IL-12活性的抗体涉及用NK细胞系孵育生物样品或其后代。确定样品中IL-12（或抗IL-12抗体）的存在或数量与由NK细胞分泌的γ干扰素（或前体活化因子或细胞因子）的量之间的相关性。为了测量抗体，将样品与IL-12预温育。然后将IL-12存在时由NK细胞分泌的细胞因子或活化因子（例如IFN-α）的水平与NK细胞分泌的细胞因子或活化因子或其后代的对照水平进行比较存在已知量的IL-12并且没有生物样品。与对照水平相比，样品中IL-12或中和抗IL12抗体的存在通过样品中分泌的细胞因子或活化因子的水平的变化，例如升高或降低来指示。当IL-12作为疫苗佐剂递送时，以及在涉及IL-12增强或减少的临床情况下，这些方法可用于监测或确定样品中IL-12的存在或IL-12产生的中和抗体，等等

10. 发明申请

WO2006081620A1 CD4+ CD25+ T-CELLS ACTIVATED TO A SPECIFIC ANTIGEN 审中-公开
标题翻译：激活到特定抗原的CD4 + CD25 + T细胞
公开(公告)号：WO2006081620A1
公开(公告)日：2006-08-10
申请号：PCT/AU2006/000133
申请日：2006-02-02
申请人： NEWSOUTH INNOVATIONS PTY LIMITED , HALL, Bruce, Milne , HODGKINSON, Suzanne, Jean
发明人： HALL, Bruce, Milne , HODGKINSON, Suzanne, Jean
IPC分类号： C12N5/08 , G01N33/50 , A61K38/20 , A61K38/21 , A61P37/08 , A61K35/12 , A61P37/06
CPC分类号： C12N5/0637 , A61K35/17 , A61K38/1793 , A61K38/20 , A61K38/2033 , A61K38/208 , A61K38/217 , A61K39/001 , A61K2039/5158 , C07K16/244 , C07K2317/76 , C12N2501/2302 , C12N2501/2304 , C12N2501/2305 , C12N2501/2312 , C12N2501/2323 , C12N2501/24 , G01N33/505 , G01N33/5094 , G01N2333/52 , G01N2333/54 , G01N2333/5406 , G01N2333/5409 , G01N2333/5434 , G01N2333/55 , G01N2333/57 , G01N2333/70514 , G01N2333/70596 , G01N2333/715 , G01N2800/245 , A61K2300/00
摘要： The invention relates to a method of assessing whether a subject comprises CD4+,CD25+ T cells that have been activated to a specific antigen. The method comprises the steps of obtaining from the subject a sample of lymphocytes comprising CD4+,CD25+ T cells, incubating at least one portion of the sample of lymphocytes so as to promote distinction of CD4+,CD25+ T cells that have been activated to the specific antigen from those CD4+,CD25+ T cells that have not been activated to the specific antigen, and thereafter determining whether CD4+,CD25+ T cells activated to the specific antigen are present in the sample. The invention further relates to methods of growing CD4+, CD25+ T cells that have been activated to a specific antigen in vitro and to methods of increasing tolerance in a subject using the CD4+, CD25+ T cells that have been grown in vitro.
摘要翻译：本发明涉及一种评估受试者是否包含已被激活到特定抗原的CD4 +，CD25 + T细胞的方法。该方法包括以下步骤：从受试者获得包含CD4 +，CD25 + T细胞的淋巴细胞样品，培养淋巴细胞样品的至少一部分，以促进已激活的CD4 +，CD25 + T细胞与特异性抗原的区别从未激活到特异性抗原的那些CD4 +，CD25 + T细胞，然后确定是否存在活化于特异性抗原的CD4 +，CD25 + T细胞存在于样品中。本发明还涉及在体外培养已被激活到特定抗原的CD4 +，CD25 + T细胞的方法和使用已经在体外培养的CD4 +，CD25 + T细胞增加受试者耐受性的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式